Apsen and Lallemand Health Solutions launched a probiotic formulation for the brain-gut axis for the Brazilian market.
Apsen (São Paulo, Brazil) and Lallemand Health Solutions (Mirabel, Canada) launched a probiotic formulation for the brain-gut axis for the Brazilian market. The formulation is sold as two finished products called Probid and Probians, both of which carry approved health claims by the Brazilian Health Authorities, ANVISA. It has five clinical studies and several pre-clinical studies that highlight eight mechanisms of action on the brain-gut axis. The modes of action for this formula have been documented by nine mechanistic studies and five human studies on the brain-gut axis.
Probid and Probians contain Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175, the combination of which is specifically designed to support mood, and reduce stress. They are approved by the Brazilian regulatory agency for the following claims:
“We are proud to be the first in Brazil to launch a specific probiotic formulation, based on two strains known for their proven effects on stress level and mood balance,” said Kleber Vargas, technical and business development vice-president at Apsen, in a press release. “Apsen invested in research to provide this evolution to the Brazilian market, with an innovative product with a full array of health benefits.”